Broncho-munal P capsules 3.5mg №10×1

Name Broncho-munal P caps 3.5 mg in a blister. in pack. No. 10×1 Storage conditions The drug should be stored out of the reach of children at a temperature of 15° to 25°C. Shelf life from the date of manufacture5 years Product descriptionHard gelatin capsules, size No3, opaque, with a white body and a blue cap; the contents of the capsules are a light beige powder. Pharmacological action Immunomodulatory drug of bacterial origin. It has an immunostimulating effect, strengthening the immune system against respiratory tract infections. After taking the capsule, the bacterial lysate accumulates in the Peyer’s patches of the gastrointestinal mucosa, in particular, located in the small intestine. Antigen-presenting cells in Peyer’s patches are activated by bacterial lysate and subsequently stimulate other cell types (B-lymphocytes) responsible for specific immunity. The number of circulating B-lymphocytes increases, which leads to an increase in the production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory mucosa and salivary glands. The drug stimulates the majority of leukocytes, which is characterized by an increase in the number of cells of the myeloid and lymphoid series, as well as a selective increase in the expression of receptors on the surface. In patients receiving the drug, the protective properties of the body against bacteria and viruses are enhanced. Clinically, the drug reduces the frequency of acute respiratory tract infections, reduces the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, and also increases the body’s resistance to infections of the respiratory system. This reduces the need for the use of other drugs, especially antibiotics. Pharmacokinetics Data on the pharmacokinetics of the drug are not available. Indications for use infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulating agent) in children aged 6 months to 12 years (for capsules 3.5 mg); infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulatory agent) in adults and children over the age of 12 years (for 7 mg capsules); for the prevention of recurrent respiratory tract infections and exacerbations of chronic bronchitis. Use during pregnancy and lactation Animal studies have not shown a negative effect on the course of pregnancy. The safety and efficacy of the drug during pregnancy and during breastfeeding have not been studied, so the use of the drug during pregnancy and lactation is contraindicated. Special instructions Possible manifestations of hypersensitivity reactions to the drug. In case of persistent gastrointestinal disorders, skin reactions, respiratory disorders or other symptoms of intolerance to the drug, the patient should stop using the drug and consult a doctor. Use in pediatrics To avoid overdose, children aged 6 months to 12 years should not be prescribed Broncho-munal® 7 mg intended for adults. Influence on the ability to drive vehicles and control mechanisms The drug does not affect the ability to concentrate and drive vehicles and mechanisms. With caution (Precautions) Children aged 6 months to 12 years are prescribed Broncho-munal® P at a dose of 3.5 mg. Contraindications: pregnancy; lactation; children under 6 months (for capsules 3.5 mg); children under 12 years (for capsules 7 mg); increased individual sensitivity to the components of the drug. at a dose of 7 mg; children aged 6 months to 12 years are prescribed Broncho-munal® P at a dose of 3.5 mg. The drug is taken in the morning on an empty stomach (30 minutes before meals) 1 caps./day. If the patient/child cannot swallow the capsule, it is recommended to open it, dissolve the contents of the capsule in a small amount of liquid (tea, milk or juice). For the prevention of infectious diseases of the respiratory tract and exacerbation of chronic bronchitis, the drug is used in three 10-day courses with 20-day intervals between them. As part of the complex therapy of acute infectious diseases of the respiratory tract, 1 capsule / day is used until the symptoms of the disease disappear, but not less than 10 days. In the next 2 months, prophylactic use of the drug is possible, 1 caps. within 10 days with a 20-day interval between courses. Overdose There are no reports of intoxication due to an overdose of the drug. The composition of the drug and the results of the study of its toxicity in animals indicate that overdose is unlikely. Side effects The drug is usually well tolerated. Most adverse reactions are categorized as moderate or moderately severe. The most common manifestation of side effects is gastrointestinal upset, skin reactions and respiratory disorders. According to WHO, undesirable effects are classified according to the frequency of development as follows: very often (? 1/10); often (?1/100, <1/10); infrequently (?1/1000, <1/100); rarely (?1/10,000, <1/1000); very rarely (<1/10,000); the frequency is unknown (the frequency of occurrence of events cannot be determined from the available data). From the digestive system: often - diarrhea, abdominal pain; frequency unknown - nausea, vomiting. From the respiratory system: often - cough; infrequently - shortness of breath. On the part of the skin and subcutaneous tissues: often - a rash. Allergic reactions: infrequently - hypersensitivity reactions (erythematous rash, generalized rash, erythema, edema, eyelid edema, facial edema, peripheral edema, swelling, swelling of the face, itching, generalized itching); frequency unknown - urticaria, angioedema. From the nervous system: the frequency is unknown - headache. General disorders: frequency unknown - fever, fatigue. CompositionStandardized lyophilisate of bacterial lysates (OM-85) 20 mg, incl. lyophilized bacterial lysates: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis 3.5 mg. Excipients: propyl gallate (anhydrous) - 0.042 mg, sodium glutamate (anhydrous) - 1.515 mg, mannitol - up to 20 mg; magnesium stearate - 3 mg, pregelatinized starch - 110 mg, mannitol - up to 200 mg. The composition of the capsule shell: indigotine (E132) - 0.009 mg, titanium dioxide (E171) - 0.98 mg, gelatin - up to 50 mg. Interaction with other drugs No interaction of the drug with other drugs has been noted. The drug can be used simultaneously with other drugs, including antibiotics. Release form Hard gelatin capsules, size No3, opaque, with a white body and a blue cap; the contents of the capsules are a light beige powder. 1 caps. standardized lyophilisate of bacterial lysates (OM-85) 20 mg, incl. lyophilized bacterial lysates: Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis 3.5 mg. Excipients: propyl gallate (anhydrous) - 0.042 mg, sodium glutamate (anhydrous) - 1.515 mg, mannitol - up to 20 mg; magnesium stearate - 3 mg, pregelatinized starch - 110 mg, mannitol - up to 200 mg. The composition of the capsule shell: indigotine (E132) - 0.009 mg, titanium dioxide (E171) - 0.98 mg, gelatin - up to 50 mg. 10 pieces. - blisters (1) - packs of cardboard. 10 pieces. - blisters (3) - packs of cardboard. Buy Broncho-munal P capsules 3.5 mg No. 10x1 Price for Broncho-munal P capsules 3.5 mg No. 10x1